. 2022; 56(2): 58-63 | DOI: 10.4274/turkderm.galenos.2022.42709 | |||
Melazmada intralezyonel traneksamik asidin etkinliği: Melazma Alan Şiddet İndeksi ve Dermatoloji Yaşam Kalite İndeksi ile değerlendirmeSneha Krishnoji Rao, Rajashekar T. S., Ashna AshrafSri Devaraj Urs Medical College, Department of Dermatology, Venereology and Leprosy, Kolar, IndiaAmaç: Melazma, çoğunlukla kadınlarda görülen, psikolojik, duygusal ve sosyal iyilik hallerinin yanı sıra yaşam kalitelerini de etkileyen yaygın bir hipermelanotik durumdur. Melazma tedaviye nispeten dirençli olmasına rağmen, bugüne kadar çeşitli tedavi seçenekleri denenmiştir. Son zamanlarda hastalığın tedavisinde mikroiğneleme ve mikroenjeksiyon ile traneksamik asit uygulanmaktadır. Bu çalışmanın amacı üçlü kombinasyon tedavisinin traneksamik asit enjeksiyonu ile terapötik etkinliğini karşılaştırmak ve tedavi öncesi ve sonrası Melazma Alanı Şiddet İndeksi (MAŞİ) ve Dermatoloji Yaşam Kalitesi İndeksi (DYKİ) skorlarını karşılaştırarak yanıtın melazma üzerindeki etkisini değerlendirmektir. Efficacy of intralesional tranexamic acid in melasma: Assessment with Melasma Area Severity Index and Dermatology Quality of Life IndexSneha Krishnoji Rao, Rajashekar T. S., Ashna AshrafSri Devaraj Urs Medical College, Department of Dermatology, Venereology and Leprosy, Kolar, IndiaBackground and Design: Melasma is a common hypermelanotic condition, mostly observed in women, which affects their psychological, emotional, and social well-being as well as their quality of life. Although melasma is relatively resistant to treatment, various therapeutic options have been attempted until date. Recently, microneedling and microinjection tranexamic acid were performed. To compare the therapeutic effectiveness of triple combination therapy with tranexamic acid injection and assess the impact of response on melasma by comparing the pre- and post-treatment Melasma Area Severity Index (MASI) and Dermatology Quality of Life Index (DLQI) scores. Materials and Methods: A total of 70 melasma patients were selected and assigned to two groups of 35 patients each based on the interventional randomized control study. One group was treated with a topical triple combination therapy-hydroquinone (2%), mometasone (0.1%), and tretinoin (0.025%), and the other group with injectable tranexamic acid. The MASI scores and DLQI were assessed for both the groups of patients at the baseline and then 6 weeks later along with serial photographs. Sneha Krishnoji Rao, Rajashekar T. S., Ashna Ashraf. Efficacy of intralesional tranexamic acid in melasma: Assessment with Melasma Area Severity Index and Dermatology Quality of Life Index. . 2022; 56(2): 58-63 Sorumlu Yazar: Rajashekar T. S., India |
|